Abstract
The fixed-dose combination of emtricitabine/tenofovir disoproxil fumarate (tenofovir DF) [Truvada®] is approved in the EU for pre-exposure prophylaxis, in conjunction with safer sex practices, to reduce the risk of sexually-acquired HIV-1 infection in adults at high risk. Once-daily administration of emtricitabine/tenofovir DF was effective in preventing HIV-1 infection in clinical trials in high-risk populations, including men who have sex with men, heterosexual HIV-1-serodiscordant couples, and heterosexual men and women. As adherence to the regimen correlates with the risk of HIV-1 infection, it is important that patient adhere to pre-exposure prophylaxis. Pre-exposure prophylaxis with the combination was generally well tolerated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
